Navigation Links
Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit

Drug safety firm BioSoteria, Inc. honored Dr. Hugh H. Tilson with the first PDSS Leadership Award at the 3rd Annual Pacific Drug Safety Summit, which took place last Friday in San Francisco. Dr. Tilson, an internationally acclaimed epidemiologist and outcomes researcher, was the moderator of the event and serves as Chairman of BioSoteria's Board of Advisors.

Emeryville, CA (PRWEB) September 30, 2009 -- BioSoteria, Inc., a drug safety services and training firm, honored Hugh H. Tilson, MD, DrPH, with the first PDSS Leadership Award at the 3rd Annual Pacific Drug Safety Summit, which took place last Friday in San Francisco. Dr. Tilson was the moderator of the event and serves as Chairman of BioSoteria's Board of Advisors.

The award was presented by Sally Van Doren, PharmD, President and Chief Executive Officer of BioSoteria, the conference organizer. In her comments to an audience of nearly 130 drug safety practitioners and providers, Dr. Van Doren remarked, "Hugh's thoughtful, candid and lively participation as keynote speaker and moderator at the three Pacific Drug Safety Summits has contributed to the annual event's unprecedented success."

Upon receiving the award, Dr. Tilson said, "I am especially honored by the words inscribed: 'Living the Vision.' Improving public health is my life's work, and I am pleased to support the vision of PDSS to educate drug safety professionals and create a forum for exchange of best pharmacovigilance practices."

About Hugh H. Tilson, MD, Dr.P.H., FISPE
An internationally acclaimed epidemiologist and outcomes researcher, Dr. Tilson's career in public health and preventive medicine spans forty years. He spent fifteen years in public service, including duties as a U.S. Army Preventive Medicine Officer in Germany; Consultant to the U.S. Office of Economic Opportunity, National Center for Health Services Research, and Veterans Administration; Local Public Health Officer and Human Services Director for Multnomah County in Portland, Oregon; and State Public Health Director for North Carolina.

Dr. Tilson then joined The Wellcome Foundation (now GlaxoSmithKline), where he introduced many epidemiologic principles and innovations to the private sector. Upon his retirement in 1996, he joined the full-time clinical faculty of University of North Carolina (UNC) School of Public Health in Chapel Hill. He is currently Adjunct Professor at UNC and at Duke University.

Besides serving as chairman of the BioSoteria Board of Advisors, Dr. Tilson is a member of the Board of Public Responsibility in Medicine & Research (PRIM&R) and the new national Public Health Accreditation Board (PHAB). He was a member of the Council for International Organisations for the Medical Sciences (CIOMS) Working Groups on Drug Safety from 1990 to 2001, and an advisor to the recent CIOMS VI and to the World Health Organization (WHO) Collaborating Centres. Dr. Tilson chaired the National Steering Committee for the Centers for Education and Research on Therapeutics (CERTs) program for the Agency for Healthcare Research and Quality (AHRQ) from 1999 to 2009. He served on the Institute of Medicine (IOM) report 'The Future of the Public's Health,' and most recently advised on the landmark 'Future of Drug Safety' IOM study. He is a co-editor of the first textbook of pharmacoepidemiology, now in its fourth edition as 'Pharmacoepidemiology and Therapeutic Risk Management.'

About the Pacific Drug Safety Summit (PDSS)
With a solid one-day agenda of contemporary drug safety and risk management topics, PDSS is a scientific conference held annually in the San Francisco Bay Area. What began as a small regional event in 2007 now attracts speakers, attendees, and sponsors across the U.S. and around the globe. For more information on PDSS09, please visit PDSS10 will be held on September 24, 2010, in San Francisco, CA. Details on the agenda, logistics, and sponsorship opportunities will be announced as they become available.

About BioSoteria, Inc.
BioSoteria provides innovative drug safety services and education to the biopharmaceutical industry and healthcare community. The company offers a wide range of pharmacovigilance services throughout the product lifecycle, including premarketing clinical safety surveillance, postmarketing safety monitoring, and risk management programs. BioSoteria-sponsored educational programs include the annual Pacific Drug Safety Summit and eLadder(TM) Safety, the first comprehensive drug safety training curriculum delivered in a true eLearning environment. To learn more about BioSoteria, visit the company's website at or call toll-free at 1-866-660-5553.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
Related Image:
Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit 
(Date:10/13/2015)... the United States , ... represents about 14% of all new cases of kidney cancer.   ... Canada and Europe .  PRCC represents ... --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces ... AB (publ) ("AstraZeneca") have completed enrolment in a global Phase II ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
(Date:10/12/2015)... 12, 2015 cell surface marker detection ... 2022, according to a new report by Grand View Research, ... in incidence of oncology diseases and other cell-associated disorders. ... to reach USD 6.49 billion by 2022, according to a ... demand can be attributed to rise in incidence of oncology ...
(Date:10/12/2015)... DIEGO , Oct. 12, 2015  Patara ... debilitating allergic and inflammatory diseases and conditions, today ... A preferred stock financing. Concurrent with the close ... entered into a Loan and Security Agreement with ... up to $7 million. Patara will use the ...
Breaking Biology Technology:
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
(Date:9/28/2015)... Synaptics Inc. (NASDAQ: SYNA ), the ... Lenovo has selected Synaptics , Natural ID ™ ... smartphone, the Vibe P1. The new Vibe P1 ... and provide swift access to applications and mobile payments ... FS4202 sensor solution utilizes AES256-bit encryption of the fingerprint ...
Breaking Biology News(10 mins):